What are the typical dosing regimens of valsartan for hypertension and heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Valsartan Typical Dosage

For hypertension, start valsartan at 80-160 mg once daily and titrate to a maximum of 320 mg daily; for heart failure with reduced ejection fraction, start at 40 mg twice daily and uptitrate to the target dose of 160 mg twice daily (320 mg total daily dose). 1

Hypertension Dosing

Starting dose: 80 mg or 160 mg once daily as monotherapy in volume-replete patients 1

Dose range: 80-320 mg once daily 1

  • The antihypertensive effect appears substantially within 2 weeks, with maximal reduction generally attained after 4 weeks 1
  • If additional blood pressure reduction is needed beyond the starting dose, increase to a maximum of 320 mg daily or add a diuretic 1
  • Adding a diuretic produces greater blood pressure reduction than dose increases beyond 80 mg 1

The evidence demonstrates dose-dependent efficacy, with reductions in systolic/diastolic blood pressure of approximately 6-9/3-5 mmHg at 80-160 mg and 9/6 mmHg at 320 mg compared to placebo 1. The optimal dose range for most patients is 80-160 mg once daily, as incremental blood pressure reductions with doses above 80 mg are relatively small 2.

Heart Failure with Reduced Ejection Fraction (HFrEF) Dosing

Starting dose: 40 mg twice daily 1

Target dose: 160 mg twice daily (320 mg total daily dose) 3, 4

Titration schedule:

  • Start at 40 mg twice daily
  • Uptitrate to 80 mg twice daily
  • Further uptitrate to 160 mg twice daily or the highest tolerated dose 1
  • Adjust dose no more frequently than every 2 weeks 3
  • Consider reducing concomitant diuretic doses during uptitration 1

The 2020 ACC/AHA guidelines specify that at minimum, patients should receive 50% of the target dose (160 mg total daily dose) unless specific contraindications exist 3. The target dose of 160 mg twice daily was established in major heart failure trials including Val-HeFT and CHARM 5.

Post-Myocardial Infarction Dosing

Starting dose: 20 mg twice daily (may initiate as early as 12 hours post-MI) 1

Titration:

  • Uptitrate within 7 days to 40 mg twice daily
  • Further titrate to target maintenance dose of 160 mg twice daily as tolerated 1
  • If symptomatic hypotension or renal dysfunction occurs, consider dose reduction 1

Pediatric Hypertension (Ages 1-16 Years)

Starting dose: 1 mg/kg once daily (up to 40 mg total), with a higher starting dose of 2 mg/kg considered when greater blood pressure reduction is needed 1

Maximum dose: 4 mg/kg once daily (maximum 160 mg daily) 1

Use of oral suspension is recommended for children aged 1-5 years and those who cannot swallow tablets 1. Note that valsartan tablets and suspension are not interchangeable on a milligram-per-milligram basis—the suspension provides 60% higher systemic exposure than tablets 1.

Important Dosing Considerations

Common pitfalls to avoid:

  • Do not combine valsartan tablets and oral suspension to achieve total dose—they are not bioequivalent 1
  • Do not withhold or reduce doses for mild or transient blood pressure reductions 6
  • Do not discontinue for mild deteriorations in renal function 6
  • In heart failure, rigid dose standardization may not be appropriate—individualize based on tolerability while targeting guideline-recommended doses 7

Dose adjustments for special populations:

  • Severe renal impairment (eGFR <30 mL/min/1.73 m²): Use lower starting doses with caution 8
  • Moderate hepatic impairment (Child-Pugh Class B): Use lower starting doses 8
  • Elderly patients (≥75 years): Consider lower starting doses 8

The evidence consistently demonstrates that higher doses within the therapeutic range provide greater clinical benefit, particularly in heart failure, where achieving target doses is associated with improved mortality and morbidity outcomes 3, 5.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.